USRE41366E1 - Total synthesis of galanthamine, analogues and derivatives thereof - Google Patents

Total synthesis of galanthamine, analogues and derivatives thereof Download PDF

Info

Publication number
USRE41366E1
USRE41366E1 US12/283,904 US28390404A USRE41366E US RE41366 E1 USRE41366 E1 US RE41366E1 US 28390404 A US28390404 A US 28390404A US RE41366 E USRE41366 E US RE41366E
Authority
US
United States
Prior art keywords
group
alkyl
formula
radicals
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US12/283,904
Other languages
English (en)
Inventor
Claude Thal
Catherine Guillou
Jean-Luc Beunard
Emmanuel Gras
Pierre Potier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) reassignment CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BEUNARD, JEAN-LUC, GRAS, EMMANUEL, POTIER, PIERRE (DECEASED, THROUGH HIS HEIRS AND/OR LEGAL REPRESENTATIVES), GUILLOU, CATHERINE, THAL, CLAUDE
Application granted granted Critical
Publication of USRE41366E1 publication Critical patent/USRE41366E1/en
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a method of synthesizing galanthamine, its analogues, and its derivatives, and to the corresponding synthesis intermediates.
  • ( ⁇ )-Galanthamine of formula (A) is an alkaloid which is isolated from the family of the Amaryllidaceae and acts as a competitive, selective, and reversible inhibitor of acetylcholinesterase (Harvey A. L. (1995), Pharmac. Ther, 68, 113).
  • this compound enhances the cognitive functions of persons suffering from Alzheimer's disease, which is characterized by damage to the cholinergic neurotransmission (Weinstock M. (1999), CNS Drugs, 12, 307).
  • At present galanthamine is sold for this indication in Austria and Sweden and should shortly be so sold in the other countries of Europe and in the United States.
  • ( ⁇ )-Galanthamine may be extracted from a variety of plant sources, in particular from Galanthus nivalis, G. narcissus, G. leucojum or G. crinium, but in very small quantities, which are inadequate for commercial use.
  • Galanthamine and its derivatives such as lycoramine are characterized by the presence of a spiro quaternary carbon, the creation of which has been found to be the limiting step in the total synthesis.
  • the inventors were the first to describe a new strategy to form this critical quaternary carbon in lycoramine (Gras E. et al., Tetrahedron Letters (1999), 40, 9243), using an intramolecular Heck reaction; they synthesized the intermediate of formula (C) and used it to prepare lycoramine by introduction of an amine group, Pictet-Spengler cyclization, and reduction with LiAlH 4 in tetrahydrofuran in accordance with the technique described by Ishisaki M. (reference already cited).
  • the inventors have now found, surprisingly, that by using an oxidizing agent mixed with a support, and starting from the compound of formula (C) or an analogue, they obtained galanthamine or its derivatives in conditions which are compatible with an industrial utilization.
  • the invention accordingly provides a method of synthesizing compounds of formula (1) in which
  • R 1 represents a hydrogen atom and R 2 represents a hydroxyl group, or R 1 and R 2 together form ⁇ O,
  • R 3 , R 4 and R 5 represent each independently of one another a hydrogen atom, a hydroxyl group or a (C 1 -C 12 )alkoxy group,
  • Z represents either two hydrogen atoms or one oxygen atom
  • X represents alternatively an oxygen atom or a sulfur atom or a nitrogen atom or an —SO group or an —SO 2 group or a group —NR 6 where R 6 is as defined above or represents an amine-protective group,
  • the support is a mixture of silica and alumina.
  • the mixture of silica and alumina is a 50/50 mixture.
  • the oxidation is performed in the presence of benzeneselinic anhydride mixed with a support, preferably an inorganic support.
  • a support preferably an inorganic support.
  • molecular sieves whose size is preferably between 3 and 5 ⁇ , and silica/alumina mixtures.
  • the compounds of formula (1) are analogues and derivatives of galanthamine, particularly basic analogues of galanthamine in which the nitrogen atom of the ring D can be converted to its salt form, and analogues containing an iminium function in the ring D, such as those described in international application WO 97/03987 and in the article by Mary A. et al. (Bioorganic and Medicinal Chemistry (1988), 6, 1835).
  • These compounds possess 3 asymmetric carbons and may therefore exist in the form of pure stereoisomers or mixtures.
  • the 3 carbon is of ⁇ configuration as in natural galanthamine.
  • the amide of formula (12) is cyclized, for example by a Pictet-Spengler-type reaction; said reaction may be performed in the presence of paraformaldehyde and trifluoroacetic acid; this gives a compound of formula (1a) whose diastereoselective reduction, for example with L-Selectride®, leads to the corresponding derivative of formula (1b) which is itself reduced under conventional conditions to give the final, corresponding compound of formula (1c)
  • optically active compounds of formula (1a) to (1c) when it is desired to obtain optically active compounds of formula (1a) to (1c), the compound (12) or (1a) is subjected to resolution under conventional conditions known to the skilled worker, and the steps described above are conducted.
  • the method allows galanthamine to be obtained in the form of the racemate or of its optically pure isomers.
  • the method according to the invention allows galanthamine, its analogues, and its derivatives to be obtained within a reasonable number of steps which are compatible with an industrial process.
  • the invention likewise provides compounds of formula (11) and (12) in which R 3 , R 4 , R 5 , R 6 , and X are as defined above, which are useful as synthesis intermediates.
  • the invention further provides compounds of formula (8) and (9) in which Hal, R 3 , R 4 , and R 5 are as defined above and X represents a sulfur atom, a nitrogen atom, an —SO group, an —SO 2 group, a group —NR 6 where R 6 is as defined above or represents an amine-protective group.
  • Elemental analysis calculated for C 17 H 19 IO 5 : C, 47.46; H, 4.45; O, 18.59; found: C, 47.34; H, 4.45; O, 18.41.
  • Elemental analysis calculated for C 17 H 18 O 5 : C, 67.54; H, 6.00; O, 26.46; found: C, 67.37; H, 6.05; O, 26.46.
  • Elemental analysis calculated for C 15 H 14 O 4 : C, 69.76; H, 5.46; O, 24.78; found: C, 69.53; H, 5.61; O, 24.76.
  • reaction mixture is kept with stirring at ambient temperature for 2 hours and then the reaction is stopped by adding saturated aqueous sodium hydrogencarbonate solution. Following extraction with ether, the organic phases are washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate and evaporated under vacuum.
  • This compound is prepared from 8-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one-[4.4′]-cyclohex-2′,5′-dien-1′-one (20) in accordance with the procedure described in steps 1.5 and 1.6 of example 1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
US12/283,904 2001-06-15 2002-06-14 Total synthesis of galanthamine, analogues and derivatives thereof Expired - Fee Related USRE41366E1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0107859A FR2826005B1 (fr) 2001-06-15 2001-06-15 Synthese totale de la galanthamine, de ses analogues et de ses derives
JP0107859 2001-06-15
PCT/FR2002/002045 WO2002102803A1 (fr) 2001-06-15 2002-06-14 Synthese totale de la galanthamine, de ses analogues et de ses derives

Publications (1)

Publication Number Publication Date
USRE41366E1 true USRE41366E1 (en) 2010-06-01

Family

ID=8864355

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/283,904 Expired - Fee Related USRE41366E1 (en) 2001-06-15 2002-06-14 Total synthesis of galanthamine, analogues and derivatives thereof
US10/480,722 Ceased US7109327B2 (en) 2001-06-15 2002-06-14 Total synthesis of galanthamine, analogues and derivatives thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/480,722 Ceased US7109327B2 (en) 2001-06-15 2002-06-14 Total synthesis of galanthamine, analogues and derivatives thereof

Country Status (7)

Country Link
US (2) USRE41366E1 (de)
EP (1) EP1458724B1 (de)
AT (1) ATE370143T1 (de)
DE (1) DE60221894T2 (de)
ES (1) ES2292776T3 (de)
FR (1) FR2826005B1 (de)
WO (1) WO2002102803A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT414125B (de) * 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln
WO2006124585A2 (en) 2005-05-13 2006-11-23 Alza Corporation Multilayer drug system for the delivery of galantamine
EP1937226A2 (de) * 2005-09-23 2008-07-02 Alza Corporation Transdermales galantaminzufuhrsystem
CN104592243B (zh) * 2014-12-19 2016-08-24 北京大学 加兰他敏和力克拉敏的不对称合成方法

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
A. L. Harvey, "The Pharmacology of Galanthamine and its Analogues", Pharmac. Ther. vol. 68, No. 1, pp. 113-128, 1995. *
Barton et al., "A Practical Catalytic Method for the Preparation of Steroidal 1,4-Dien-3-ones by Oxygen Atom Transfer from Iodoxybenzene to Diphenyl Di-selende", J. Chem. Soc. Perkin Trans. I, 1982, pp. 1947-1952). *
Barton et al., "Dehydrogenation of Lactones using Benzeneseleninic Anhydride", J. Chem. Soc. Perkin Trans. I, 1982, pp. 1919-1922. *
Barton et al., "Dehydrogenation of Steroidal and Triterpenoid Ketones using Benzene-seleninic Anhydride", J.C.S.Perkin I (1980), pp. 2209-2212. *
Barton et al., "Phenol Oxidation and Biosynthesis. Part V. The Synthesis of Galanthamine", J. Chem. Soc. (1962), pp. 806-817. *
Czollner et al., "New Kilogram-Synthesis of the Anti-Alzheimer Drug (-)-Galathamine", Tetrahedron Letters 39 (1998), pp. 2087-2088. *
Czollner et al., "New Kilogram-Synthesis of the Anti-Alzheimer Drug (−)-Galathamine", Tetrahedron Letters 39 (1998), pp. 2087-2088. *
Gras et al., "A formal sythesis of (±O lycoramine via an intramolecular Heck reaction", Tetrahedron Letters 40 (1999), pp. 9243-2944. *
Ishizaki et al., "Synthetic Approaches toward Spiro[2,3-dihydro-4H-1-benzopyran-4,1′-cyclohexan]-2-one Derivatives via Radical Reactions: Total Synthesis of (±)-Lycoramine", J. Org. Chem. 1993, 58, 3877-3885. *
Ishizaki et al., "Synthetic Approaches toward Spiro[2,3-dihydro-4H-1-benzopyran-4,1'-cyclohexan]-2-one Derivatives via Radical Reactions: Total Synthesis of (±)-Lycoramine", J. Org. Chem. 1993, 58, 3877-3885. *
Krikorian et al., "New Achievements in the Field of Intramolecular Phenolic Coupling Reactions, Using Hypervalent (III) Iodine Reagent: Synthesis of Galanthamine", Synthetic Communications, 30(16), 2833-2846 (2000), pp. 2833-2846. *
Parsons et al., "A general approach to the galanthamine ring system", Tetrahedron Letters 42 (2001), pp. 2209-2211. *
Pilger et al., "A New Stereoselective Approach Towards the Galanthamine Ring System via an Intramolecular Heck Reaction", Synlett 2000, No. 8, pp. 1163-1165. *
T. G. Back, "Dehydrogenation of Hydrazines and of 4-Azacholestan-3-one with Benzenseleninic Acid and Benzeneseleninic Anhydride", J.C.S. Chem. Comm., 1978 (pp. 278-279). *
Trost et al., "Enantioselective Total Synthesis of (-)-Galanthamine", J. Am. Chem. Soc. 2000, 122, pp. 11262-11263. *
Trost et al., "Enantioselective Total Synthesis of (−)-Galanthamine", J. Am. Chem. Soc. 2000, 122, pp. 11262-11263. *
Weinstock, "Selectivity of Cholinesterase Inhibition, Clinical Implications for the Treatment of Alzheimer's Disease", CNS Drugs Oct. 12, 1999 (4), pp. 307-323. *

Also Published As

Publication number Publication date
EP1458724B1 (de) 2007-08-15
US7109327B2 (en) 2006-09-19
WO2002102803A1 (fr) 2002-12-27
ATE370143T1 (de) 2007-09-15
DE60221894D1 (de) 2007-09-27
ES2292776T3 (es) 2008-03-16
US20050065338A1 (en) 2005-03-24
DE60221894T2 (de) 2008-04-30
EP1458724A1 (de) 2004-09-22
FR2826005B1 (fr) 2004-07-16
FR2826005A1 (fr) 2002-12-20

Similar Documents

Publication Publication Date Title
NO331656B1 (no) Framgangsmate for syntetisering av camptothesin relaterte forbindelser
Reitz et al. A directed metalation of N-tert-butyl-N-methyl-2-methoxybenzamide. Short syntheses of 2-methoxy-6-methylbenzoic acid and lunularic acid
US5744605A (en) Intermediates in the synthesis of (+) camptothecin and related compounds and synthesis thereof
US5521310A (en) Process to obtain benzoxazines to be used for the synthesis of ofloxazine, levofloxazine and derivatives
USRE41366E1 (en) Total synthesis of galanthamine, analogues and derivatives thereof
NZ228614A (en) Furo (3,4-c) pyridine enantiomers; preparation by stereospecific process and therapeutic compositions
EP1860103B1 (de) Verbindung gegen krebs, zwischenprodukt dafür und verfahren zur herstellung beider
Kato et al. Total synthesis of (+)-and (-)-galanthamine
CA2236420A1 (en) Method for preparing camptothecin derivatives
Iyer et al. Silver (I) Oxide Catalyzed Oxidation of o-Allyl-and o-(1-Propenyl) phenols.
US3726924A (en) Method for the preparation of tris (dimethylamino) methane
KR20000064811A (ko) 테트라히드로인돌리진 유도체의 제조법
US4105670A (en) Spiro[cyclopropane-1,2'-indolin]-3'-ones
Shin et al. Convenient synthesis of 3-aminocoumarin derivatives by the condensation of 1, 4-diacetyl-or 3-substituent-2, 5-piperazinediones with various salicylaldehyde derivatives.
Yamato et al. Synthesis and antitumor activity of tropolone derivatives. 3
Tsai et al. A New Synthesis of Angelicin from 7‐Hydroxycoumarin via C‐Propenation‐O‐Vinylation and Ring‐Closing Metathesis
US7423152B2 (en) Process for the manufacture of intermediates in camptothecin production
US5721371A (en) Synthesis of substituted pterocarpans
Yoshida et al. A novel synthesis of selenium-containing heterocyclic compounds. Carbonylation of ortho-substituted anilines with carbon monoxide in the presence of selenium
KR19990008411A (ko) 4-히드록시-2-피롤리돈의 개량 제법
US5801250A (en) Process for the stereoselective production of nitro-enamine compounds
KR100226622B1 (ko) 무스콘의 신규합성중간체 및 그의 제조방법
KR101519011B1 (ko) 비스무트 촉매를 이용한 피라노쿠마린 유도체의 제조방법
Aubert et al. Synthesis of dipyrazolo [3, 4-b: 4′, 3′-f] azepines and dithieno [2, 3-b: 3′, 2′ f] azepines from 1-substituted 2, 7-dichloro-4, 5-dihydro-1 H-azepine-3, 6-dicarbaldehydes
Tokumitsu et al. Reactions of 1, 1-Diamino-2-nitroethylenes with Dimethyl Acetylenedicarboxylate.

Legal Events

Date Code Title Description
AS Assignment

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:THAL, CLAUDE;GUILLOU, CATHERINE;BEUNARD, JEAN-LUC;AND OTHERS;SIGNING DATES FROM 20100112 TO 20100114;REEL/FRAME:024072/0449

CC Certificate of correction
CC Certificate of correction
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees